Shire Unit Settles Genzyme False Advertising Suit

Law360, New York (February 25, 2014, 7:03 PM EST) -- A Massachusetts federal judge on Tuesday pulled the plug on a Genzyme Corp. suit accusing Shire Human Genetic Therapies Inc. of misleading consumers by advertising its genetic disease drug VPRIV as superior to Genzyme's Cerezyme after both parties said they'd reached a settlement.

U.S. District Judge Richard G. Stearns signed off on a consent order drafted by both parties ending the litigation on the condition that Shire agree to never again to distribute a press release from June 2012 that touted research findings in a way...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.